Joel Greenblatt's BIIB Position Overview
Joel Greenblatt (via Gotham Asset Management, LLC) currently holds 270.5K shares of Biogen Inc. (BIIB) worth $37.89 M, representing 0.16% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 47 quarters.
Based on 13F filings since 2013, Joel Greenblatt has maintained a long-term strategic position in BIIB, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2016, adding 214.1K shares. Largest reduction occurred in Q3 2016, reducing 122.6K shares.
Analysis based on 13F filings available since 2013 Q2
Joel Greenblatt's Biogen (BIIB) Holding Value Over Time
Track share changes against reported price movement
Quarterly Biogen (BIIB) Trades by Joel Greenblatt
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2014 | +3,931 | New Buy | 3,931 | $305.77 |
| Q2 2014 | -3,931 | Sold Out | 3,931 | $0.00 |
| Q3 2014 | +31,391 | New Buy | 31,391 | $330.80 |
| Q4 2014 | -26,379 | Reduce 84.03% | 5,012 | $339.39 |
| Q1 2015 | -5,012 | Sold Out | 5,012 | $0.00 |
| Q3 2015 | +9,410 | New Buy | 9,410 | $291.82 |
| Q4 2015 | +75,167 | Add 798.80% | 84,577 | $306.35 |
| Q1 2016 | +214,096 | Add 253.14% | 298,673 | $260.32 |
| Q2 2016 | +69,422 | Add 23.24% | 368,095 | $241.82 |
| Q3 2016 | -122,627 | Reduce 33.31% | 245,468 | $313.03 |
| Q4 2016 | -5,157 | Reduce 2.10% | 240,311 | $283.58 |
| Q1 2017 | +35,149 | Add 14.63% | 275,460 | $273.42 |
| Q2 2017 | -112,996 | Reduce 41.02% | 162,464 | $271.36 |
| Q3 2017 | -99,425 | Reduce 61.20% | 63,039 | $313.12 |
| Q4 2017 | +24,835 | Add 39.40% | 87,874 | $318.57 |
| Q1 2018 | +23,927 | Add 27.23% | 111,801 | $273.82 |
| Q2 2018 | -26,694 | Reduce 23.88% | 85,107 | $290.23 |
| Q3 2018 | -5,836 | Reduce 6.86% | 79,271 | $353.31 |
| Q4 2018 | +27,164 | Add 34.27% | 106,435 | $300.92 |
| Q1 2019 | +44,817 | Add 42.11% | 151,252 | $236.38 |
| Q2 2019 | +4,034 | Add 2.67% | 155,286 | $233.87 |
| Q3 2019 | +19,741 | Add 12.71% | 175,027 | $232.82 |
| Q4 2019 | -15,261 | Reduce 8.72% | 159,766 | $296.73 |
| Q1 2020 | -25,791 | Reduce 16.14% | 133,975 | $316.38 |
| Q2 2020 | -34,093 | Reduce 25.45% | 99,882 | $267.55 |
| Q3 2020 | -68,839 | Reduce 68.92% | 31,043 | $283.67 |
| Q4 2020 | -8,035 | Reduce 25.88% | 23,008 | $244.87 |
| Q1 2021 | -8,184 | Reduce 35.57% | 14,824 | $279.75 |
| Q2 2021 | -11,914 | Reduce 80.37% | 2,910 | $346.39 |
| Q3 2021 | +10,832 | Add 372.23% | 13,742 | $283.00 |
| Q4 2021 | -3,658 | Reduce 26.62% | 10,084 | $239.88 |
| Q1 2022 | +15,155 | Add 150.29% | 25,239 | $210.59 |
| Q2 2022 | -9,092 | Reduce 36.02% | 16,147 | $203.94 |
| Q3 2022 | -5,031 | Reduce 31.16% | 11,116 | $267.00 |
| Q4 2022 | +7,253 | Add 65.25% | 18,369 | $276.92 |
| Q1 2023 | +1,505 | Add 8.19% | 19,874 | $278.03 |
| Q2 2023 | +11,274 | Add 56.73% | 31,148 | $284.85 |
| Q3 2023 | -11,698 | Reduce 37.56% | 19,450 | $257.01 |
| Q4 2023 | -15,766 | Reduce 81.06% | 3,684 | $258.77 |
| Q1 2024 | -3,684 | Sold Out | 3,684 | $0.00 |
| Q2 2024 | +23,557 | New Buy | 23,557 | $231.82 |
| Q3 2024 | +18,887 | Add 80.18% | 42,444 | $193.84 |
| Q4 2024 | +47,182 | Add 111.16% | 89,626 | $152.92 |
| Q1 2025 | +9,602 | Add 10.71% | 99,228 | $136.84 |
| Q2 2025 | +64,261 | Add 64.76% | 163,489 | $125.59 |
| Q3 2025 | +107,009 | Add 65.45% | 270,498 | $140.08 |
Joel Greenblatt's Biogen Investment FAQs
Joel Greenblatt first purchased Biogen Inc. (BIIB) in Q1 2014, acquiring 3,931 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt has held Biogen Inc. (BIIB) for 47 quarters since Q1 2014. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's largest addition to Biogen Inc. (BIIB) was in Q1 2016, adding 298,673 shares worth $77.75 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Joel Greenblatt's firm, Gotham Asset Management, LLC, owns 270,498 shares of Biogen Inc. (BIIB), valued at approximately $37.89 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Biogen Inc. (BIIB) represents approximately 0.16% of Joel Greenblatt's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Joel Greenblatt's peak holding in Biogen Inc. (BIIB) was 368,095 shares, as reported at the end of Q2 2016. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.